Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

November 14, 2012

Primary Completion Date

August 6, 2019

Study Completion Date

August 30, 2022

Conditions
Mucinous Adenocarcinoma of the ColonMucinous Adenocarcinoma of the RectumSignet Ring Adenocarcinoma of the ColonSignet Ring Adenocarcinoma of the RectumStage IV Colon CancerStage IV Rectal Cancer
Interventions
BIOLOGICAL

aflibercept

4 mg/kg as a 1-hour IV(intervenous) infusion

DRUG

oxaliplatin

85 mg/m2 IV infused over 2 hours

DRUG

leucovorin

200 mg/m2 (Or levoleucovorin 100 mg/m2. If leucovorin is not available due to drug shortages the regimen should be administered with the leucovorin omitted) IV over 2 hours. Alternatively, leucovorin may be administered (via separate infusion lines) concurrently with oxaliplatin

DRUG

fluorouracil

400 mg/m2 IV bolus over 5-15 minutes, then 2400 mg/m2 continuous IV infusion over 46 hours.

OTHER

Correlative Studies

Patients are required to have tissue available before enrolling on the study. A fresh biopsy is only required if there is insufficient material for analysis. Repeat tumor biopsies after 8 weeks of therapy are optional and will only be performed at the Ohio State University Medical Center.

PROCEDURE

DCE MRI

Images at weeks 0, and after 8 weeks +/- 1 week of treatment (after Cycle 2).

RADIATION

f18FDG-PET

18FDG-PET is a functional imaging technique that relies on tumor uptake of radiolabeled tracer 18 fluorodeoxyglucose (18FDG). FDG-PET is a widely-used imaging modality in the detection and monitoring of a variety of metastatic cancers, including colorectal cancer (99-102).

PROCEDURE

PET (positron emission tomography)

Correlative studies

Trial Locations (6)

10461

Montefiore Medical Center, The Bronx

14263

Roswell Park Cancer Institute, Buffalo

23298

Virginia Commonwealth University, Richmond

27599

University of North Carolina, Chapel Hill

43210

Ohio State University Medical Center, Columbus

48109

University of Michigan, Ann Arbor

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

John Hays

OTHER

NCT01652196 - Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer | Biotech Hunter | Biotech Hunter